Diagnosis of latent tuberculosis infection before initiation of anti-tumor necrosis factor therapy using both tuberculin skin test and QuantiFERON-TB Gold In Tube assay

Scandinavian Journal of Infectious Diseases

Volumn 46, Issue 11, 2014, Pages 763-769

  Kim, Ho Cheol ^a   Jo, Kyung Wook ^a   Jung, Young Ju ^a   Yoo, Bin ^a   Lee, Chang Keun ^a   Kim, Yong Gil ^a   Yang, Suk Kyun ^a   Byeon, Jeong Sik ^a   Kim, Kyung Jo ^a   Ye, Byong Duk ^a   Shim, Tae Sun ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

Latent tuberculosis infection; QuantiFERON TB Gold In Tube; Tuberculin skin tests; Tumor necrosis factor

Indexed keywords

ADALIMUMAB; ETANERCEPT; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; ISONIAZID; ISONIAZID PLUS RIFAMPICIN; RIFAMPICIN; STEROID; TUMOR NECROSIS FACTOR INHIBITOR; TUBERCULOSTATIC AGENT; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTHRALGIA; ARTICLE; AUTOIMMUNE DISEASE; BIOASSAY; CAUSE OF DEATH; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CHRONIC LIVER DISEASE; CHRONIC LUNG DISEASE; COMORBIDITY; CROHN DISEASE; DIABETES MELLITUS; DRUG ERUPTION; DRUG SENSITIVITY; FALSE NEGATIVE RESULT; FEMALE; FOLLOW UP; HUMAN; IMMUNE MEDIATED INFLAMMATORY DISEASE; LATENT TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MYALGIA; MYCOBACTERIUM BOVIS BCG; MYCOBACTERIUM TUBERCULOSIS TEST KIT; NEOPLASM; QUANTIFERON TB GOLD IN TUBE ASSAY; RHEUMATOID ARTHRITIS; SIDE EFFECT; SKIN INDURATION; STEROID THERAPY; SWEATING; TREATMENT OUTCOME; TUBERCULIN TEST; ULCERATIVE COLITIS; ANTAGONISTS AND INHIBITORS; AUTOIMMUNE DISEASES; IMMUNOLOGY; INTERFERON GAMMA RELEASE ASSAY; MIDDLE AGED; PROCEDURES; RETROSPECTIVE STUDY;

ADULT; ANTIBIOTICS, ANTITUBERCULAR; ANTITUBERCULAR AGENTS; AUTOIMMUNE DISEASES; FEMALE; HUMANS; INTERFERON-GAMMA RELEASE TESTS; ISONIAZID; LATENT TUBERCULOSIS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RIFAMPIN; TUBERCULIN TEST; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84912029838     PISSN: 00365548     EISSN: 16511980     Source Type: Journal    
DOI: 10.3109/00365548.2014.938691     Document Type: Article

References (32)

1. Keane J, Gershon S, Wise R P, Mirabile-Levens E, Kasznica J , Schwieterman WD, et al. Tuberculosis associated with infLiximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001;345:1098-104
2. Beglinger C, Dudler J, Mottet C, Nicod L, Seibold F , Villiger PM, et al. Screening for tuberculosis infection before the initiation of an anti-TNF-alpha therapy. Swiss Med Wkly 2007;137:620-2
3. Nordgaard-Lassen I, Dahlerup J F, BelarDe, Gerstoft J , Kjeldsen J, Kragballe K, et al. Guidelines for screening, prophylaxiSand criticaLinformation prior to initiating anti- TNF-alpha treatment. Dan Med J 2012;59:C4480
4. Cantini F, Niccoli L, Goletti D. T uberculosis risk in patients treated with non-anti-tumor necrosis factor- β (TNF- β) targeted biologicSand recently licensed TNF- β inhibitors: data from clinical trialSand national registries. J Rheumatol Suppl 2014;91:56-64
5. Ponce de Leon D, Acevedo-Vasquez E, Sanchez-Torres A , Cucho M, Alfaro J, Perich R, et al. Attenuated response to purifi ed protein derivative in patients with rheumatoid arthritis: study in a population with a high prevalence of tuberculosis. Ann Rheum Dis 2005;64:1360-1
6. Richeldi L, Losi M, DAmico R, Luppi M, Ferrari A , Mussini C, et al. Performance of tests for latent tuberculosis in different groups of immunocompromised patients. Chest 2009;136:198-204
7. Diel R, Goletti D, Ferrara G, Bothamley G, Cirillo D , Kampmann B, et al. Interferon- gamma; release assays for the diagnosis of latent Mycobacterium tuberculosis infection: a systematic revieWand meta-analysis. Eur Respir J 2011;37 : 88-99
8. Diel R, Loddenkemper R, Nienhaus A. P redictive value of interferon- gamma; release assaySand tuberculin skin testing for progression from latent TB infection to disease state: Ameta-analysis. Chest 2012;142:63-75
9. Smith R, Cattamanchi A, Steingart K R, Denkinger C , Dheda K, Winthrop KL, et al. Interferon- gamma; release assays for diagnosis of latent tuberculosis infection: evidence in immune-mediated infl ammatory disorders. Curr Opin Rheumatol 2011;23:377-84
10. Goletti D, Sanduzzi A, Delogu G. P erformance of the tuberculin skin test and interferon- gamma; release assays: an update on the accuracy, cutoff stratifi cation, and new potentiaLimmunebased approaches. J Rheumatol Suppl 2014;91:24-31
11. Mariette X, Baron G, Tubach F, Liote F, Combe B , Miceli-Richard C, et al. Influence of replacing tuberculin skin test with ex vivo interferon gamma; release assays on decision to administer prophylactiCantituberculosiSantibiotics before anti-TNF therapy. Ann Rheum Dis 2012;71:1783-90
12. Jung Y J, Lyu J, Yoo B, Lee C K, Kim Y G, Yang S K, et al. Combined use of a TST and the T-SPOT ® .TB assay for latent tuberculosis infection diagnosis before anti-TNF- α treatment. Int J Tuberc Lung Dis 2012;16:1300-6
13. Jung YJ, Lee JY, Jo KW, Yoo B, Lee CK, Kim YG, et al. The either test positive strategy for latent tuberculous infection before anti-tumour necrosis factor treatment. Int J Tuberc Lung Dis 2014;18:428-34
14. NationaLinstitute for Health and ClinicaLexcellence. T uberculosis: Clinical diagnosiSand management of tuberculosis, and measures for its prevention and control. London: NationaLinstitute for Health and ClinicaLexcellence (UK);2011
15. Bartalesi F, Goletti D, Spinicci M, Cavallo A, Attala L, Mencarini J, et al. Serial QuantiFERON TB-Gold In-Tube testing during LTBI therapy in candidates for TNFi treatment. J Infect 2013;66:346-56
16. American Thoracic Society (ATS), Centers for Disease Control and Prevention (CDC). Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med 2000;161:S221-47
17. Steffen RE, Caetano R, Pinto M, Chaves D, Ferrari R , Bastos M, et al. Cost-effectiveness of Quantiferon-TB ® Gold-In-Tube versus tuberculin skin testing for contact screening and treatment of latent tuberculosis infection in Brazil. PloS One 2013;8:e59546
18. Kim S Y, Jung G S, Kim S K, Chang J, Kim M S, Kim Y S, et al. Comparison of the tuberculin skin test and interferongamma release assay for the diagnosis of latent tuberculosis infection before kidney transplantation. Infection 2013;41 : 103-10
19. Scrivo R, Sauzullo I, Mengoni F, Iaiani G, Vestri AR , Priori R, et al. SeriaLinterferon- gamma; release assays for screening and monitoring of tuberculosis infection during treatment with biologiCagents. Clin Rheumatol 2012;31:1567-75
20. Pareek M, Bond M, Shorey J, Seneviratne S, Guy M , White P, et al. Community-baseDevaluation of immigrant tuberculosis screening using interferon gamma; release assaySand tuberculin skin testing: observational study anDeconomiCanalysis. Thorax 2013;68:230-9
21. Lagrange P H, Thangaraj S K, Dayal R, Deshpande A , Ganguly NK, Girardi E, et al. A toolbox for tuberculosis (TB) diagnosis: an Indian multicentric study (2006-2008). Evaluation of QuantiFERON-TB Gold In Tube for TB diagnosis. PLoS One 2013;8:e73579
22. Lee JY, Choi HJ, P ark IN, Hong SB, Oh YM, Lim CM, et al. Comparison of two commerciaLinterferon-gamma assays for diagnosing Mycobacterium tuberculosis infection. Eur Respir J 2006;28:24-30
23. Lai CC, T an CK, Lin SH, Liao CH, H uang YT, H sueh PR. Diagnostic performance of whole-blood interferon-gamma assay anDenzyme-linked immunospot assay for active tuberculosis. Diagn MicrobioLinfect Dis 2011;71:139-43
24. Chapman A L, MunkantAm, Wilkinson KA, P athan A A , Ewer K, Ayles H, et al. Rapid detection of active and latent tuberculosis infection in HIV-positive individuals by enumeration of Mycobacterium tuberculosis -specific T cells. AIDS 2002;16:2285-93
25. LalVani A, Nagvenkar P, Udwadia Z, Pathan AA , Wilkinson KA, Shastri JS, et al. Enumeration of T cells specific for RD1-encoded antigens suggests a high prevalence of latent Mycobacterium tuberculosis infection in healthy urban Indians. J Infect Dis 2001;183:469-77
26. Higuchi K, Sekiya Y, Igari H, Watanabe A, HaradAn. Comparison of specificities between two interferon-gamma release assays in Japan. Int J Tuberc Lung Dis 2012;16 : 1190-2
27. Vassilopoulos D, Tsikrika S, Hatzara C, Podia V, Kandili A , Stamoulis N, et al. Comparison of two gamma interferon release assaySand tuberculin skin testing for tuberculosis screening in a cohort of patients with rheumatic diseases starting anti-tumor necrosis factor therapy. Clin Vaccine Immunol 2011;18:2102-8
28. Mancuso J D, Mazurek G H, Tribble D, Olsen C , Aronson NE, Geiter L, et al. Discordance among commercially available diagnostics for latent tuberculosis infection. Am J Respir Crit Care Med 2012;185:427-34
29. Mazurek GH, J ereb J, Vernon A, LoBue P, Goldberg S , Castro K. Updated guidelines for using interferon gamma release assays to detect Mycobacterium tuberculosis infection - United States, 2010. MMWR Recomm Rep 2010; 59:1-25
30. Jo KW, Hong Y, Jung YJ, Yoo B, Lee CK, Kim YG, et al. Incidence of tuberculosis among anti-tumor necrosis factor users in patients with a previous historYof tuberculosis. Respir Med 2013;107:1797-802
31. Tubach F, Salmon D, Ravaud P, Allanore Y, Goupille P , Breban M, et al. Risk of tuberculosis is higher with antitumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the three-year prospective French Research Axed on Tolerance of Biotherapies registry. Arthritis Rheum 2009;60:1884-94
32. Dixon WG, Watson K, Lunt M, Hyrich KL, Silman AJ , Symmons DP. Rates of serious infection, including sitespecifiCand bacteriaLintracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2006;54:2368-76